loading page

Nirmatrelvir and ritonavir combination against COVID-19 caused by omicron BA.2.2: A single-center large observational study
  • +5
  • Zhangzhang Chen,
  • Can Chen,
  • Ranyi Li,
  • Shuliang Xing,
  • Lei Cao,
  • Yue Qu,
  • Qianzhou Lv,
  • Xiaoyu Li
Zhangzhang Chen
Zhongshan Hospital Fudan University

Corresponding Author:chen.zhangzhang@zs-hospital.sh.cn

Author Profile
Can Chen
Zhongshan Hospital Fudan University
Author Profile
Ranyi Li
Zhongshan Hospital Fudan University
Author Profile
Shuliang Xing
Science and Education office Shanghai Geriatric Medical Center
Author Profile
Lei Cao
Zhongshan Hospital Fudan University
Author Profile
Yue Qu
Alfred Hospital and Monash University
Author Profile
Qianzhou Lv
Zhongshan Hospital Fudan University
Author Profile
Xiaoyu Li
Zhongshan Hospital Fudan University
Author Profile

Abstract

Objective: To assess the effectiveness and safety of nirmatrelvir-ritonavir in the treatment of mild-to-moderate COVID-19 caused by the omicron BA. 2. 2 variant. Methods: An observational study was conducted retrospectively to review the outcomes of mild-to-moderate COVID-19 patients admitted between 26 April and 30 June, 2022. Patients’ baseline characteristics were collected and assessed. Participants in the intervention group were administered nirmatrelvir-ritonavir in addition to standard care, whereas those in the control group only received standard care. The primary outcome was the duration between symptoms onset or the initial positive RT-PCR test and the subsequent conversion to a negative result. Results: The analysis included 324 patients who were administered nirmatrelvir-ritonavir and an equal number of control patients. The patient characteristics in both groups were evenly matched. The average duration from symptoms onset or the initial positive RT-PCR to negative conversion was similar in both groups (16.2±5.0 vs. 16.1±6.3 days, P=0.83). Control patients exhibited slower conversion in comparison to patients who received nirmatrelvir-ritonavir treatment within 10 days of symptom onset. Conclusion: These findings suggest that administering nirmatrelvir-ritonavir within 10 days of symptom onset could potentially reduce the time it takes for SARS-CoV-2-infected patients to negative RT-PCR results, thereby expanding the current usage guidelines for nirmatrelvir-ritonavir.